Karyopharm Therapeutics (Nasdaq: KPTI) announced the initiation of its Phase 2 study of Selinexor (KPT-330) in patients with Richter's transformation ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Karyopharm Therapeutics (KPTI) Misses Q3 EPS by 9cNovember 10, 2014 7:21 AM Form 8-K Karyopharm Therapeutics For: Nov 10November 10, 2014 7:08 AM Karyopharm Initiates Registration-Directed Clinical Study of Selinexor (KPT-330) in Patients With Richter's TransformationNovember 10, 2014 7:00 AM